NASDAQ:TCONTRACON Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding TRACON Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.93 -0.01 (-0.52 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's Range$1.87Now: $1.93▼$1.9750-Day Range$1.89MA: $2.04▼$2.3352-Week Range$0.95Now: $1.93▼$6.40Volume163,380 shsAverage Volume298,770 shsMarket Capitalization$10.62 millionP/E RatioN/ADividend YieldN/ABeta2.06 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead product candidate is TRC105, an endoglin antibody, which is in randomized Phase III clinical trial for angiosarcoma; Phase I/II clinical trial for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trial for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trial for wet AMD. The company also develops TRC102, a small molecule that is in Phase II clinical trial for mesothelioma, Phase I clinical trial for solid tumors and lung cancer, and Phase I/II clinical trial for solid tumors and lymphomas; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trial for the treatment prostate cancer. In addition, it is developing TJ004309, a novel humanized antibody against CD73 that is in Phase I clinical trial to treat patients with solid tumors through a strategic collaboration and clinical trial agreement with I-Mab Biopharma. The company has license agreements with Ambrx, Inc.; Santen Pharmaceutical Co. Ltd.; Roswell Park Cancer Institute and Health Research Inc.; Case Western Cancer Center; and Lonza Sales AG, as well as a cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingTRACON Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, TRACON Pharmaceuticals has a potential upside of 107.3% from its current price of $1.93.Amount of Analyst CoverageTRACON Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesTRACON Pharmaceuticals has received 239 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTRACON Pharmaceuticals has received 193 “underperform” votes. (Add your “underperform” vote.)Community SentimentTRACON Pharmaceuticals has received 55.32% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about TRACON Pharmaceuticals and other stocks. Vote “Outperform” if you believe TCON will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TCON will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTRACON Pharmaceuticals does not currently pay a dividend.Dividend GrowthTRACON Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TRACON Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $52,042.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 23.30% of the stock of TRACON Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 23.02% of the stock of TRACON Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for TRACON Pharmaceuticals are expected to grow in the coming year, from ($3.11) to ($2.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TRACON Pharmaceuticals is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TRACON Pharmaceuticals is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTRACON Pharmaceuticals has a P/B Ratio of 2.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.99 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TCON Previous Symbol CUSIPN/A CIK1394319 Webwww.traconpharma.com Phone858-550-0780Debt Debt-to-Equity Ratio1.23 Current Ratio1.71 Quick Ratio1.71Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3 million Price / Sales3.54 Cash FlowN/A Price / Cash FlowN/A Book Value$0.67 per share Price / Book2.88Profitability EPS (Most Recent Fiscal Year)($7.47) Net Income$-22,670,000.00 Net MarginsN/A Return on Equity-422.70% Return on Assets-93.85%Miscellaneous Employees26 Outstanding Shares5,500,000Market Cap$10.62 million Next Earnings Date8/5/2020 (Estimated) OptionableNot Optionable NASDAQ:TCON Rates by TradingView Receive TCON News and Ratings via Email Sign-up to receive the latest news and ratings for TCON and its competitors with MarketBeat's FREE daily newsletter. TRACON Pharmaceuticals (NASDAQ:TCON) Frequently Asked Questions How has TRACON Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? TRACON Pharmaceuticals' stock was trading at $1.41 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TCON shares have increased by 36.9% and is now trading at $1.93. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of TRACON Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for TRACON Pharmaceuticals. When is TRACON Pharmaceuticals' next earnings date? TRACON Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for TRACON Pharmaceuticals. How were TRACON Pharmaceuticals' earnings last quarter? TRACON Pharmaceuticals Inc (NASDAQ:TCON) announced its earnings results on Wednesday, May, 13th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.13) by $0.35. View TRACON Pharmaceuticals' earnings history. What price target have analysts set for TCON? 1 Wall Street analysts have issued twelve-month price objectives for TRACON Pharmaceuticals' stock. Their forecasts range from $4.00 to $4.00. On average, they expect TRACON Pharmaceuticals' stock price to reach $4.00 in the next year. This suggests a possible upside of 107.3% from the stock's current price. View analysts' price targets for TRACON Pharmaceuticals. Has TRACON Pharmaceuticals been receiving favorable news coverage? News headlines about TCON stock have been trending negative on Saturday, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. TRACON Pharmaceuticals earned a daily sentiment score of -2.8 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an effect on the company's share price in the immediate future. View the latest news about TRACON Pharmaceuticals. Are investors shorting TRACON Pharmaceuticals? TRACON Pharmaceuticals saw a decline in short interest in June. As of June 15th, there was short interest totaling 22,500 shares, a decline of 46.9% from the May 31st total of 42,400 shares. Based on an average daily volume of 311,000 shares, the short-interest ratio is currently 0.1 days. Currently, 0.5% of the shares of the stock are short sold. View TRACON Pharmaceuticals' Current Options Chain. Who are some of TRACON Pharmaceuticals' key competitors? Some companies that are related to TRACON Pharmaceuticals include aTyr Pharma (LIFE), Pharmacyte Biotech (PMCB), Allena Pharmaceuticals (ALNA), Acorda Therapeutics (ACOR), Titan Pharmaceuticals (TTNP), Genetic Technologies (GENE), Entera Bio (ENTX), BioCardia (BCDA), Seneca Biopharma (SNCA), Vitro Diagnostics (VODG), Enzon Pharmaceuticals (ENZN), Neuralstem (CUR), Gene Biotherapeutics (CRXM), CytRx (CYTR) and Innate Pharma (IPHA). View all competitors. What other stocks do shareholders of TRACON Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include SCYNEXIS (SCYX), Verastem (VSTM), Inovio Pharmaceuticals (INO), Opko Health (OPK), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), T2 Biosystems (TTOO), Gilead Sciences (GILD), Novavax (NVAX) and Progenics Pharmaceuticals (PGNX). Who are TRACON Pharmaceuticals' key executives? TRACON Pharmaceuticals' management team includes the following people: Dr. Charles P. Theuer, CEO, Pres, Principal Financial Officer, Principal Accounting Officer & Director (Age 55)Mr. Scott B. Brown, VP & Head of Fin.Dr. Sharon Real, Exec. VP of Product Devel. (Age 55)Ms. Bonne Adams, Exec. VP of Clinical Operations (Age 42)Ms. Suzy Benedict, Sr. VP of Regulatory Affairs When did TRACON Pharmaceuticals IPO? (TCON) raised $47 million in an IPO on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers. What is TRACON Pharmaceuticals' stock symbol? TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON." How do I buy shares of TRACON Pharmaceuticals? Shares of TCON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is TRACON Pharmaceuticals' stock price today? One share of TCON stock can currently be purchased for approximately $1.93. How big of a company is TRACON Pharmaceuticals? TRACON Pharmaceuticals has a market capitalization of $10.62 million and generates $3 million in revenue each year. The biopharmaceutical company earns $-22,670,000.00 in net income (profit) each year or ($7.47) on an earnings per share basis. TRACON Pharmaceuticals employs 26 workers across the globe. What is TRACON Pharmaceuticals' official website? The official website for TRACON Pharmaceuticals is www.traconpharma.com. How can I contact TRACON Pharmaceuticals? TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The biopharmaceutical company can be reached via phone at 858-550-0780 or via email at [email protected] This page was last updated on 7/4/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
